Pfizer (NYSE:PFE) Given New $33.00 Price Target at Guggenheim

Pfizer (NYSE:PFE) had its price target increased by Guggenheim from $31.00 to $33.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Royal Bank Of Canada upped their target price on shares of Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a research report on Wednesday. BMO Capital Markets reduced their price objective on Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a research note on Monday, July 13th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. UBS Group lifted their target price on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Argus set a $40.00 target price on Pfizer in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $29.94.

Pfizer Stock Down 2.9%

PFE opened at $29.91 on Thursday. The company has a quick ratio of 0.96, a current ratio of 1.42 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $170.46 billion, a PE ratio of 42.72, a price-to-earnings-growth ratio of 2.04 and a beta of 0.31. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44. The firm has a 50-day simple moving average of $28.72 and a two-hundred day simple moving average of $26.88.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.74 by $0.13. Pfizer had a net margin of 6.34% and a return on equity of 19.88%. The business had revenue of $16.58 billion during the quarter, compared to analyst estimates of $15.85 billion. During the same quarter last year, the business earned $0.87 earnings per share. Pfizer’s quarterly revenue was down .4% compared to the same quarter last year. Analysts forecast that Pfizer will post 3.02 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 5.8%. Pfizer’s payout ratio is presently 245.71%.

Institutional Trading of Pfizer

Several institutional investors and hedge funds have recently made changes to their positions in PFE. Bank of America Corp DE purchased a new position in Pfizer in the 2nd quarter worth $1,049,602,000. BlackRock Inc. grew its stake in shares of Pfizer by 6.3% during the 2nd quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. Nykredit A S purchased a new position in Pfizer in the second quarter valued at $205,774,000. Assenagon Asset Management S.A. raised its holdings in Pfizer by 96.0% in the 2nd quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after purchasing an additional 5,829,204 shares during the period. Finally, State Street Corp lifted its position in shares of Pfizer by 1.8% during the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock valued at $7,394,749,000 after buying an additional 5,501,032 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat adjusted earnings expectations in Q3 and raised its 2026 outlook to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Non-COVID products grew 7% operationally, while launched and acquired products rose 32%, supporting the case that its newer portfolio can offset declines elsewhere. Pfizer Q3 earnings call highlights
• Positive Sentiment: Guggenheim raised its price target from $31 to $33 and assigned a Buy rating; Scotiabank also raised its target and maintained an outperform rating, signaling improving analyst optimism. Guggenheim rating information
• Positive Sentiment: Coverage describes Pfizer’s dividend as well-covered and its valuation as modest, which may appeal to income-focused investors. Pfizer stock looks attractive for income investors
• Neutral Sentiment: Call-option purchases surged well above average, reflecting bullish positioning, though options activity can be speculative and does not establish a sustained outlook.
• Neutral Sentiment: Pfizer is advancing a Phase 3 study of a monthly obesity treatment. Progress could strengthen its pipeline, but the report provides no trial results yet. Pfizer advances monthly obesity drug study
• Neutral Sentiment: Goldman Sachs maintained a Hold rating, a counterpoint to the more positive target changes. Goldman Sachs remains a Hold
• Negative Sentiment: Q3 coverage flagged margin compression. Even with raised guidance and cost reductions, Pfizer must show that new-product growth can translate into durable profitability. Pfizer Q3 deep dive

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.